Research Collaboration to Develop Next Generation Cell-based Therapies for Solid Tumors $40 Million Raised by CERo to Facilitate...

-- Research Collaboration to Develop Next Generation Cell-based Therapies for Solid Tumors -- -- $40 Million Raised by CERo to Facilitate...

Xconomy Boston — Gene editing biotech Beam Therapeutics raised $180 million in its initial public offering Wednesday after offering 48...

SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators...

Company Raises $145 Million in Eighteen Months to Complete Development and Early Commercialization of Breakthrough DNA Sequencing...

Indigo raises an additional $200M, comprised of $175M in convertible equity and $25M in debt, bringing its total capital raised to...

Phase 1/2 trial ongoing with multiple patients dosed in GB1275 monotherapy dose escalation – GB1275 granted Orphan Drug Designation for...

Program addresses aggressive cancers with RTK (HER2, ERBB3, FGFR1, FGFR2) and KRAS mutations SAN DIEGO, November 5, 2019 — eFFECTOR...

EMERYVILLE, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company...